Historical Press Releases

2012

Soligenix Demonstrates Robust Stability Results with its SGX204 Anthrax Vaccine

Princeton, NJ – January 18, 2012 – Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today results from long-term stability...

Soligenix Receives $574,000 in Non-Dilutive Financing from New Jersey’s Technology Business Tax Certificate Transfer Program

Princeton, NJ – January 26, 2012 – Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that it has recently...

Soligenix Announces 1 for 20 Reverse-Split of its Common Stock

Princeton, NJ – January 31, 2012 – Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced it has filed a Certificate of Amendment to...

Soligenix Demonstrates Positive Proof of Concept with its Proprietary Vaccine Thermostabilization Technology

Princeton, NJ – February 6, 2012 – Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today results from preclinical studies of...

Soligenix Announces Results from its Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis

Princeton, NJ – February 10, 2012 – Soligenix, Inc. (OTCBB: SNGXD) (Soligenix or the Company), a development stage biopharmaceutical company, announced preliminary results today from a Phase...

Soligenix Announces Positive Survival Results of SGX202 in Radiation Injury

Princeton, NJ – February 21, 2012 – Soligenix, Inc. (OTCBB: SNGXD) (Soligenix or the Company), a development stage biopharmaceutical company, announced today further promising preliminary...

Soligenix Reports Year-End 2011 Financial Results and Highlights Recent Accomplishments

Princeton, NJ – March 27, 2012 – Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today its financial results for the year...

Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability

Princeton, NJ – April 25, 2012 – Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today further progress in the development of...

Soligenix Reports First Quarter 2012 Financial Results and Highlights Recent Accomplishments

Princeton, NJ – May 14, 2012 – Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today its financial results for the quarter...

Soligenix Announces Collaboration with Infectious Disease Research Institute to Develop Thermostabilized Biodefense Vaccines Utilizing Novel Adjuvants

Princeton, NJ – June 27, 2012 – Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that it has entered into a...

Soligenix Announces $600,000 NIAID SBIR Grant Award Supporting Further Evaluation of OrbeShieldTM as a Treatment for Acute Radiation Syndrome

Princeton, NJ – July 17, 2012 – Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that the National Institute of Allergy...

Soligenix Announces $300,000 NCI SBIR Grant Award Supporting a Phase 2 Trial of orBec® as a Treatment for Chronic GI GVHD

Princeton, NJ – September 4, 2012 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that the National Cancer Institute...

Soligenix Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate SGX203 as Therapy for Pediatric Crohn’s Disease

Princeton, NJ – September 6, 2012 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that the Food and Drug...

Soligenix Announces Presentation of OrbeShieldTM Data at Annual Radiation Research Society Meeting

Princeton, NJ – September 28, 2012 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that results of a study in a...

Soligenix Announces Formation of Acute Radiation Syndrome Scientific Advisory Board

Princeton, NJ – October 3, 2012 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today the formation of a Scientific...

Soligenix Expands Pipeline with Acquisition of Novel Innate Defense Regulator Clinical Program

Princeton, NJ – December 18, 2012 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today the acquisition of a novel drug...

Soligenix Regains North American and European Commercial Rights to Oral BDP

Princeton, NJ – December 27, 2012 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, today announced that it has regained the North...

FDA Grants Soligenix Orphan Drug Designation for OrbeShieldTM for Treatment after Exposure to a Radiological Disaster

Princeton, NJ – January 2, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that the Office of Orphan Products...